Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CABA NYSE:DNA NASDAQ:KURA NASDAQ:PROK On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCABACabaletta Bio$2.32-4.9%$1.81$0.99▼$5.46$223.18M3.012.43 million shs1.62 million shsDNAGinkgo Bioworks$14.81-0.4%$12.40$5.00▼$16.85$880.30M1.541.69 million shs1.65 million shsKURAKura Oncology$9.43-3.8%$7.74$5.41▼$19.73$850.61M0.321.78 million shs1.52 million shsPROKProKidney$2.96+2.1%$2.54$0.46▼$7.13$853.42M1.722.39 million shs3.49 million shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCABACabaletta Bio0.00%+2.52%+43.53%+61.59%-42.72%DNAGinkgo Bioworks-7.86%+12.65%+33.78%+33.12%+78.51%KURAKura Oncology+2.40%+9.25%+19.22%+68.67%-45.68%PROKProKidney+5.84%+16.94%+28.89%-22.25%+71.09%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCABACabaletta Bio$2.32-4.9%$1.81$0.99▼$5.46$223.18M3.012.43 million shs1.62 million shsDNAGinkgo Bioworks$14.81-0.4%$12.40$5.00▼$16.85$880.30M1.541.69 million shs1.65 million shsKURAKura Oncology$9.43-3.8%$7.74$5.41▼$19.73$850.61M0.321.78 million shs1.52 million shsPROKProKidney$2.96+2.1%$2.54$0.46▼$7.13$853.42M1.722.39 million shs3.49 million shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCABACabaletta Bio0.00%+2.52%+43.53%+61.59%-42.72%DNAGinkgo Bioworks-7.86%+12.65%+33.78%+33.12%+78.51%KURAKura Oncology+2.40%+9.25%+19.22%+68.67%-45.68%PROKProKidney+5.84%+16.94%+28.89%-22.25%+71.09%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCABACabaletta Bio 2.80Moderate Buy$14.50525.00% UpsideDNAGinkgo Bioworks 1.67Reduce$9.00-39.21% DownsideKURAKura Oncology 2.69Moderate Buy$24.10155.57% UpsidePROKProKidney 2.17Hold$6.25111.15% UpsideCurrent Analyst Ratings BreakdownLatest CABA, DNA, PROK, and KURA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/30/2025KURAKura OncologyHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$40.009/27/2025CABACabaletta BioWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025DNAGinkgo BioworksWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025KURAKura OncologyWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025PROKProKidneyWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/5/2025CABACabaletta BioCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$15.009/4/2025KURAKura OncologyGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageNeutral8/25/2025DNAGinkgo BioworksBTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetSell$6.00 ➝ $9.008/18/2025PROKProKidneyZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold8/11/2025KURAKura OncologyJMP SecuritiesSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetMarket Outperform$28.00 ➝ $24.008/8/2025DNAGinkgo BioworksCowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy(Data available from 10/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCABACabaletta BioN/AN/AN/AN/A$3.12 per shareN/ADNAGinkgo Bioworks$230.82M3.80N/AN/A$13.17 per share1.12KURAKura Oncology$53.88M15.19N/AN/A$5.32 per share1.77PROKProKidney$80K10,888.36N/AN/A($3.41) per share-0.87Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCABACabaletta Bio-$115.86M-$2.71N/AN/AN/AN/A-92.11%-74.08%11/13/2025 (Estimated)DNAGinkgo Bioworks-$547.03M-$5.86N/AN/AN/A-136.56%-43.25%-22.29%11/11/2025 (Estimated)KURAKura Oncology-$173.98M-$2.26N/AN/AN/AN/A-52.32%-29.59%11/6/2025 (Estimated)PROKProKidney-$61.19M-$0.57N/AN/AN/AN/AN/A-17.11%11/11/2025 (Estimated)Latest CABA, DNA, PROK, and KURA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q2 2025PROKProKidney-$0.14-$0.13+$0.01-$0.13N/A$0.22 million8/7/2025Q2 2025CABACabaletta Bio-$0.71-$0.73-$0.02-$0.73$4.17 millionN/A8/7/2025Q2 2025DNAGinkgo Bioworks-$1.44-$1.10+$0.34-$1.10$41.60 million$49.60 million8/7/2025Q2 2025KURAKura Oncology$0.15-$0.75-$0.90-$0.75$64.95 million$15.29 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCABACabaletta BioN/AN/AN/AN/AN/ADNAGinkgo BioworksN/AN/AN/AN/AN/AKURAKura OncologyN/AN/AN/AN/AN/APROKProKidneyN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCABACabaletta BioN/A4.784.78DNAGinkgo BioworksN/A5.415.41KURAKura Oncology0.026.166.16PROKProKidneyN/A11.4811.48Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCABACabaletta BioN/ADNAGinkgo Bioworks78.63%KURAKura OncologyN/APROKProKidney51.59%Insider OwnershipCompanyInsider OwnershipCABACabaletta Bio11.25%DNAGinkgo Bioworks9.72%KURAKura Oncology6.40%PROKProKidney41.49%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCABACabaletta Bio5091.46 million81.18 millionOptionableDNAGinkgo Bioworks64059.20 million53.45 millionOptionableKURAKura Oncology13086.80 million81.24 millionOptionablePROKProKidney3294.28 million172.18 millionOptionableCABA, DNA, PROK, and KURA HeadlinesRecent News About These CompaniesProKidney (NASDAQ:PROK) Trading 8.1% Higher - Should You Buy?October 1, 2025 | marketbeat.comProKidney Corp. (NASDAQ:PROK) Given Consensus Rating of "Hold" by AnalystsSeptember 28, 2025 | americanbankingnews.comProKidney Corp. (NASDAQ:PROK) Given Consensus Recommendation of "Hold" by AnalystsSeptember 28, 2025 | marketbeat.comProKidney Corp (PROK) Touts Reparencel Therapy for GrowthSeptember 21, 2025 | msn.com11 Best Healthcare Penny Stocks to Buy NowSeptember 19, 2025 | insidermonkey.comProKidney: Slow-Burning 'Buy' Opportunity Based On 2027 Approval Of Kidney Disease TherapySeptember 19, 2025 | seekingalpha.comProKidney (NASDAQ:PROK) Shares Down 6.9% - Here's What HappenedSeptember 14, 2025 | marketbeat.comProKidney (NASDAQ:PROK) Shares Up 21.1% - Still a Buy?September 13, 2025 | marketbeat.comProKidney Leads Our Trio Of Promising Penny StocksSeptember 12, 2025 | finance.yahoo.comProKidney Corp. (PROK) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference TranscriptSeptember 8, 2025 | seekingalpha.comNuveen LLC Makes New Investment in ProKidney Corp. $PROKSeptember 8, 2025 | marketbeat.comChronic Kidney Disease Market Outlook 2034 – Clinical Trials, Market Size, Medication, Prevalence, Companies by DelveInsightSeptember 3, 2025 | theglobeandmail.comProKidney Corp. (PROK) Presents At Citi's Biopharma Back To School Conference TranscriptSeptember 3, 2025 | seekingalpha.comProKidney to Participate in Two Upcoming Conferences: the Citi Biopharma Back to School Conference and the Morgan Stanley Global Healthcare ConferenceAugust 27, 2025 | globenewswire.comProKidney Reports 78 Percent Gain in Q2August 14, 2025 | theglobeandmail.comCiti Reaffirms Their Buy Rating on ProKidney (PROK)August 14, 2025 | theglobeandmail.comProKidney reports larger second-quarter loss as key studies continueAugust 14, 2025 | journalnow.comJProKidney Corp. Reports Q2 2025 Financial ResultsAugust 13, 2025 | msn.comProKidney reports Q2 EPS (13c), consensus (14c)August 12, 2025 | msn.comProKidney Reports Second Quarter 2025 Financial Results and Provides Regulatory and Clinical UpdatesAugust 12, 2025 | globenewswire.comProKidney Corp. (PROK) - Yahoo FinanceAugust 9, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCABA, DNA, PROK, and KURA Company DescriptionsCabaletta Bio NASDAQ:CABA$2.32 -0.12 (-4.92%) Closing price 04:00 PM EasternExtended Trading$2.36 +0.04 (+1.51%) As of 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis. It also develops DSG3-CAART, which is in Phase I/II clinical trial for the treatment of mucosal pemphigus vulgaris; and MuSK-CAART, an investigational cell therapy that is in Phase I/II clinical trial for treating patients with anti- muscle-specific kinase antibody positive myasthenia gravis. It has a collaboration with the University of Pennsylvania and the Children's Hospital of Philadelphia; Nanjing IASO Biotherapeutics Co., Ltd; Oxford Biomedica; and WuXi Advanced Therapies, Inc. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.Ginkgo Bioworks NYSE:DNA$14.80 -0.07 (-0.44%) Closing price 03:59 PM EasternExtended Trading$14.96 +0.16 (+1.05%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.Kura Oncology NASDAQ:KURA$9.43 -0.37 (-3.78%) Closing price 04:00 PM EasternExtended Trading$9.50 +0.07 (+0.74%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification. The company was founded in 2014 and is headquartered in San Diego, California.ProKidney NASDAQ:PROK$2.96 +0.06 (+2.07%) Closing price 04:00 PM EasternExtended Trading$2.95 -0.01 (-0.34%) As of 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease. ProKidney Corp. founded in 2015 and is headquartered in Winston-Salem, North Carolina. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas AMD Could Double From Here—Thanks to Its Blockbuster OpenAI Deal EA’s $55 Billion Deal Spurs a Shake-Up in the Gaming Sector 3 Dividend Aristocrats to Buy Before Year’s End The Juice Is Loose: Why Plug Power's Rally Is Just the Beginning Joby's Stock Rallies as Public Flights Validate Global Game Plan SharkNinja Is Flashing a Buy Signal the Market Is Ignoring Why Semtech Stock Is Rallying After Its NVIDIA Setback Marvell Insiders Buy Shares—Should Investors Follow Suit? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
